This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)

This study has been completed.
Information provided by (Responsible Party):
Puma Biotechnology, Inc. Identifier:
First received: December 17, 2008
Last updated: May 10, 2012
Last verified: May 2012
This study will examine the bioavailability (the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action) of two tablet formulations of Neratinib (HKI-272) compared to the capsule formulation.

Condition Intervention Phase
Healthy Subjects Drug: neratinib Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Dose Bioavailability Study of 2 New Tablet Formulations of Neratinib Compared With a Reference Capsule in Healthy Adult Subjects

Resource links provided by NLM:

Further study details as provided by Puma Biotechnology, Inc.:

Primary Outcome Measures:
  • Blood will be collected to determine the pharmacokinetics of the various formulations of HKI-272 [ Time Frame: 6 weeks ]

Enrollment: 24
Study Start Date: January 2009
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
40-mg tablet
Drug: neratinib
Experimental: 2
240-mg tablet
Drug: neratinib
Experimental: 3
80-mg capsule
Drug: neratinib


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Healthy male and female subjects, ages 18-50.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00814060

United States, Washington
Tacoma, Washington, United States, 98418
Sponsors and Collaborators
Puma Biotechnology, Inc.
Study Director: Puma Biotechnology
  More Information

Responsible Party: Puma Biotechnology, Inc. Identifier: NCT00814060     History of Changes
Other Study ID Numbers: 3144A1-1117
Study First Received: December 17, 2008
Last Updated: May 10, 2012 processed this record on August 22, 2017